ChemoCentryx Inc (NASDAQ: CCXI) tanked roughly 60% in the stock market on Friday as approval for its drug for an autoimmune disease hung in the balance. ChemoCentryx is seeking FDA approval for Avacopan as a treatment for Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV...

https://invezz.com/news/2021/05/07/heres-why-chemocentryx-plunged-60-in-the-stock-market-on-friday/

#InvezzNews